Elpida Therapeutics initiates MELPIDA trial for SPG50 using AAV9 gene therapy
Elpida Therapeutics is conducting a trial for MELPIDA, a gene therapy targeting SPG50, focusing on safety and tolerability.
Asset / Drug
Drug and asset intelligence for SPG50 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.